Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hormone Replacement Therapy and Development of New Asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS: A Secondary Analysis of the EFRAIM Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mast cell tryptase enhances wound healing by promoting migration in human bronchial epithelial cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Agreement Between Transcutaneous Monitoring and Arterial Blood Gases During COPD Exacerbation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Unique Aspects of Asthma in Women

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Treating severe asthma: targeting the IL-5 pathway

    Research output: Contribution to journalReviewResearchpeer-review

  • Liam G Heaney
  • Luis Perez de Llano
  • Mona Al-Ahmad
  • Vibeke Backer
  • John Busby
  • Giorgio Walter Canonica
  • George C Christoff
  • Borja G Cosio
  • J Mark FitzGerald
  • Enrico Heffler
  • Takashi Iwanaga
  • David J Jackson
  • Andrew N Menzies-Gow
  • Nikolaos G Papadopoulos
  • Andriana I Papaioannou
  • Paul E Pfeffer
  • Todor A Popov
  • Celeste M Porsbjerg
  • Chin Kook Rhee
  • Mohsen Sadatsafavi
  • Yuji Tohda
  • Eileen Wang
  • Michael E Wechsler
  • Marianna Alacqua
  • Alan Altraja
  • Leif Bjermer
  • Unnur S Björnsdóttir
  • Arnaud Bourdin
  • Guy G Brusselle
  • Roland Buhl
  • Richard W Costello
  • Mark Hew
  • Mariko Koh Siyue
  • Sverre Lehmann
  • Lauri Lehtimäki
  • Matthew Peters
  • Camille Taillé
  • Christian Taube
  • Trung N Tran
  • James Zangrilli
  • Lakmini Bulathsinhala
  • Victoria A Carter
  • Isha Chaudhry
  • Neva Eleangovan
  • Naeimeh Hosseini
  • Marjan Kerkhof
  • Ruth B Murray
  • Chris A Price
  • David B Price
View graph of relations

BACKGROUND: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts.

RESEARCH QUESTION: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables?

STUDY DESIGN AND METHODS: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC).

RESULTS: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P < .001) and worse lung function (postbronchodilator % predicted FEV 1, 76.1% vs 89.3%; P = .027) than those with a noneosinophilic phenotype. Patients with noneosinophilic phenotypes were more likely to be women (81.5% vs 62.9%; P = .047), to have eczema (20.8% vs 8.5%; P = .003), and to use anti-IgE (32.1% vs 13.4%; P = .004) and leukotriene receptor antagonists (50.0% vs 28.0%; P = .011) add-on therapy.

INTERPRETATION: According to this multicomponent, consensus-driven, and evidence-based eosinophil gradient algorithm (using variables readily accessible in real life), the severe asthma eosinophilic phenotype was more prevalent than previously identified and was phenotypically distinct. This pragmatic gradient algorithm uses variables readily accessible in primary and specialist care, addressing inherent issues of phenotype heterogeneity and phenotype instability. Identification of treatable traits across phenotypes should improve therapeutic precision.

Original languageEnglish
Issue number3
Pages (from-to)814-830
Number of pages17
Publication statusPublished - Sep 2021

    Research areas

  • Asia, Europe, International Severe Asthma Registry, Middle East, North America

ID: 65065897